Lots of vegetables, olive oil, nuts, whole grains, and occasional fish–these foods form the core of not only my diet but also ...

Scientists have failed to show that weight-loss wonder drug semaglutide slows the progress of Alzheimer's disease (AD), as ...

Shares of Novo Nordisk (NYSE: NVO) fell on Monday, finishing down 5.6%. The drop comes as the S&P 500 and the Nasdaq ...

We break down the current state of frontotemporal dementia, from bvFTD to PPA, and why 'promising' therapies are still far ...

Shares of Biogen rose 3% following news of Novo's Alzheimer's trial failure. Biogen and partner Eisai's Leqembi and rival Eli ...

Novo Nordisk A/S’ wild card bet that its GLP-1 receptor agonist semaglutide could be used to treat Alzheimer’s disease has ...

The biomarker improvements in the EVOKE studies are worth noting, observed Howard Fillit, MD, of the Alzheimer's Drug ...

Despite encouraging biomarker shifts, oral semaglutide failed to slow cognitive decline in early Alzheimer’s, leading to an early end of the trial extension.

Combining genetic risk with cardiovascular disease risk factors — such as high LDL cholesterol, obesity, and hypertension — ...

An oral version of semaglutide, the active ingredient in blockbuster drugs Ozempic and Wegovy, failed to slow the progression ...

Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s ...

Based on the efficacy results, Novo Nordisk has made the decision to discontinue the 1-year extension periods for these trials.